Poolbeg Pharma CEO says POLB-001 patent win strengthens Big Pharma partnership potential

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington talked with Proactive's Stephen Gunnion about the company securing its first national patent for POLB-001 targeting cancer immunotherapy-induced cytokine release syndrome (CRS). Skillington explained that the patent, granted by IP Australia, covers the use of p38 MAPK inhibitors, including POLB-001, to prevent and treat CRS. He highlighted that the protection is broad and supported by proprietary data generated by the company, foll ...